journal article·2019-04

A Dual‐Bioresponsive Drug‐Delivery Depot for Combination of Epigenetic Modulation and Immune Checkpoint Blockade

Huitong Ruan, Quanyin Hu, Di Wen, Qian Chen, Guojun Chen, Yifei Lu, Jinqiang Wang, Hao Cheng, Weiyue Lu, Zhen Gu

Advanced Materials· Volume 31· Issue 17
Publisher page

Abstract

Abstract Patients with advanced melanoma that is of low tumor‐associated antigen (TAA) expression often respond poorly to PD‐1/PD‐L1 blockade therapy. Epigenetic modulators, such as hypomethylation agents (HMAs), can enhance the antitumor immune response by inducing TAA expression. Here, a dual bioresponsive gel depot that can respond to the acidic pH and reactive oxygen species (ROS) within the tumor microenvironment (TME) for codelivery of anti‐PD1 antibody (aPD1) and Zebularine (Zeb), an HMA, is engineered. aPD1 is first loaded into pH‐sensitive calcium carbonate nanoparticles (CaCO 3 NPs), which are then encapsulated in the ROS‐responsive hydrogel together with Zeb (Zeb‐aPD1‐NPs‐Gel). It is demonstrated that this combination therapy increases the immunogenicity of cancer cells, and also plays roles in reversing immunosuppressive TME, which contributes to inhibiting the tumor growth and prolonging the survival time of B16F10‐melanoma‐bearing mice.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Cancer Immunotherapy and Biomarkers · Nanoplatforms for cancer theranostics · Immunotherapy and Immune Responses

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Bioengineering University of California Los Angeles CA 90095 USA

Department of Pharmaceutics School of Pharmacy Key Laboratory of Smart Drug Delivery Fudan University Shanghai 201203 China

California NanoSystems Institute Jonsson Comprehensive Cancer Center and Center for Minimally Invasive Therapeutics University of California Los Angeles CA 90095 USA

Joint Department of Biomedical Engineering University of North Carolina at Chapel Hill and North Carolina State University Raleigh NC 27695 USA

Department of Materials Science and Engineering Drexel University Philadelphia PA 19104 USA

Funding

University of North Carolina at Chapel Hill · Alfred P. Sloan Foundation · National Natural Science Foundation of China · China Scholarship Council

References (55)

Show source-provided references
1. 10.1016/j.coi.2011.12.00910.1016/j.coi.2011.12.009 ↗
2. 10.1172/JCI8001110.1172/JCI80011 ↗
3. 10.1126/science.aaa817210.1126/science.aaa8172 ↗
4. 10.1038/nrd.2015.3510.1038/nrd.2015.35 ↗
5. 10.1038/ncomms1319310.1038/ncomms13193 ↗
6. 10.1200/JCO.2013.53.010510.1200/JCO.2013.53.0105 ↗
7. 10.1093/annonc/mdx68010.1093/annonc/mdx680 ↗
8. 10.1016/S0140-6736(17)31046-210.1016/S0140-6736(17)31046-2 ↗
9. 10.1158/2326-6066.CIR-15-005910.1158/2326-6066.CIR-15-0059 ↗
10. 10.1200/JCO.2016.72.134010.1200/JCO.2016.72.1340 ↗
11. 10.1056/NEJMoa151066510.1056/NEJMoa1510665 ↗
12. 10.1016/j.cell.2017.06.00710.1016/j.cell.2017.06.007 ↗
13. 10.1002/adhm.20180109910.1002/adhm.201801099 ↗
14. 10.1038/nature1398810.1038/nature13988 ↗
15. 10.1016/j.cell.2017.01.01710.1016/j.cell.2017.01.017 ↗
16. 10.1038/sj.onc.120560210.1038/sj.onc.1205602 ↗
17. 10.1073/pnas.93.14.714910.1073/pnas.93.14.7149 ↗
18. Héninger E. · Front. Immunol. · 2015 · 6 · 29
19. 10.1186/1471-2407-2-2910.1186/1471-2407-2-29 ↗
20. 10.1186/1471-2407-4-6510.1186/1471-2407-4-65 ↗
21. 10.1038/sj.onc.120967810.1038/sj.onc.1209678 ↗
22. 10.1158/0008-5472.CAN-10-244210.1158/0008-5472.CAN-10-2442 ↗
23. 10.1007/s00262-008-0562-x10.1007/s00262-008-0562-x ↗
24. 10.1111/j.1365-2141.2012.09225.x10.1111/j.1365-2141.2012.09225.x ↗
25. 10.3390/cancers302167210.3390/cancers3021672 ↗
26. 10.18632/oncotarget.178210.18632/oncotarget.1782 ↗
27. 10.1158/2326-6066.CIR-15-007310.1158/2326-6066.CIR-15-0073 ↗
28. 10.1007/s00262-012-1204-x10.1007/s00262-012-1204-x ↗
29. 10.1007/s00262-016-1868-810.1007/s00262-016-1868-8 ↗
30. 10.18632/oncotarget.154210.18632/oncotarget.1542 ↗
31. 10.1038/leu.2013.35510.1038/leu.2013.355 ↗
32. 10.1056/NEJMoa150182410.1056/NEJMoa1501824 ↗
33. 10.1016/j.cell.2018.09.03510.1016/j.cell.2018.09.035 ↗
34. 10.1016/j.cell.2017.08.03110.1016/j.cell.2017.08.031 ↗
35. 10.1200/JCO.2016.67.247710.1200/JCO.2016.67.2477 ↗
36. 10.1182/blood-2015-06-64807110.1182/blood-2015-06-648071 ↗
37. 10.1186/s13643-018-0805-710.1186/s13643-018-0805-7 ↗
38. 10.1002/hon.204610.1002/hon.2046 ↗
39. Gnyszka A. · Anticancer Res. · 2013 · 33 · 2989
40. 10.1196/annals.1359.03710.1196/annals.1359.037 ↗
41. 10.1080/0036552060087419810.1080/00365520600874198 ↗
42. 10.1007/s11060-015-1965-010.1007/s11060-015-1965-0 ↗
43. 10.1002/jnr.1016010.1002/jnr.10160 ↗
44. Sasaki M. · Cancer Res. · 2001 · 61 · 4809
45. 10.1084/jem.181.2.79910.1084/jem.181.2.799 ↗
46. 10.1038/sj.gt.330286410.1038/sj.gt.3302864 ↗
47. 10.1093/jnci/95.5.39910.1093/jnci/95.5.399 ↗
48. 10.1158/1940-6207.CAPR-07-000810.1158/1940-6207.CAPR-07-0008 ↗
49. 10.1021/la011736s10.1021/la011736s ↗
50. 10.1038/s41565-018-0319-410.1038/s41565-018-0319-4 ↗
51. 10.1021/acsnano.7b0815210.1021/acsnano.7b08152 ↗
52. 10.1126/scitranslmed.aan368210.1126/scitranslmed.aan3682 ↗
53. 10.1126/science.aam936110.1126/science.aam9361 ↗
54. 10.1021/acsami.7b0368210.1021/acsami.7b03682 ↗
55. Nishiyama N. · Cancer Res. · 2003 · 63 · 8977